Posts by: Ana de Barros, PhD

News

The Scottish region of Fife has launched one of the world’s first local care frameworks for Huntington’s disease, putting local staff and families at the forefront of work to ... Read more

June 12, 2018June 12, 2018

Novel Spotlights Daily Struggles of Patients and Families

News

“You Me Everything,” a novel about a single mom whose mother is diagnosed with Huntington’s disease, is helping to raise awareness of the condition. The story is also drawing ... Read more

June 7, 2018June 7, 2018

Program Provides Second Opinion About Rare Disease Diagnosis, Care

News

A Rare Conditions Care Value (RCCV) program providing second opinions from experts for patients with rare diseases like Huntington’s disease was launched recently by two U.S. health management companies, Express Scripts and Pinnacle Care. ... Read more

May 17, 2018May 17, 2018

AllianceRx Walgreens Prime and Walgreens Offer New Specialty Therapies, Including Austedo for Huntington’s

News

AllianceRx Walgreens Prime and Walgreens now have several new limited distribution therapies available for its specialty patients, including Teva Pharmaceuticals’ Austedo (deutetrabenazine) for Huntington’s disease. Austedo was approved in ... Read more

May 14, 2018May 14, 2018

UK Group Leads Community-building Charge for Huntington’s Disease Awareness Week

News

For Huntington’s Disease Awareness Week, the Huntington’s Disease Association in the U.K. has a few suggestions for ways to bring the community together and educate others. Because Huntington’s is a rare disease, few ... Read more

March 22, 2018March 22, 2018

Huntington’s and ALS Nonprofits Partner with Teva to Discover New Therapeutic Targets

News

Three organizations fighting neurodegenerative diseases have teamed up to challenge researchers around the world to come up with new treatment approaches for central nervous system (CNS) disorders. The Huntington’s ... Read more

March 15, 2018March 15, 2018

MMJ BioScience Licensed in Canada to Make Cannabis-based Medicine for Huntington’s Studies

News

MMJ BioScience received a licence from Health Canada to develop cannabis-derived products based on proprietary formulations for the treatment of Huntington’s disease and multiple sclerosis (MS). The license will enable ... Read more

March 6, 2018March 6, 2018

HDSA Expands List of Huntington’s Disease Centers of Excellence to 43 for 2018

News

The Huntington’s Disease Society of America (HDSA) recently announced that 43 Huntington’s disease (HD) care facilities are now designated as HDSA Centers of Excellence for 2018 — up from ... Read more

March 1, 2018March 1, 2018

Emerald Health’s Huntington’s Therapy Candidate EHP-102 Granted FDA Orphan Drug Status

News

The U.S. Food and Drug Administration recently granted orphan drug status to Emerald Health’s EHP-102, an investigative therapy for Huntington’s disease. EHP-102 is a patented cannabigerol (CBG) derivative in development for the ... Read more

February 13, 2018March 13, 2018

Wave Life Sciences and Takeda Collaborating on Huntington’s Therapies

News

Wave Life Sciences and Takeda Pharmaceutical Company are teaming up to develop nucleic acid therapies for central nervous system disorders such as Huntington’s disease. The agreement gives Takeda the option ... Read more

Posts by: Ana de Barros, PhD

Ana de Barros, PhD

Scotland’s Fife Launches Groundbreaking Local Care Frameworks for Huntington’s Disease

Novel Spotlights Daily Struggles of Patients and Families

Program Provides Second Opinion About Rare Disease Diagnosis, Care

AllianceRx Walgreens Prime and Walgreens Offer New Specialty Therapies, Including Austedo for Huntington’s

UK Group Leads Community-building Charge for Huntington’s Disease Awareness Week

Huntington’s and ALS Nonprofits Partner with Teva to Discover New Therapeutic Targets

MMJ BioScience Licensed in Canada to Make Cannabis-based Medicine for Huntington’s Studies

HDSA Expands List of Huntington’s Disease Centers of Excellence to 43 for 2018

Emerald Health’s Huntington’s Therapy Candidate EHP-102 Granted FDA Orphan Drug Status

Wave Life Sciences and Takeda Collaborating on Huntington’s Therapies

Pin It on Pinterest